With CHF20 million (£12.4 million) under its belt from two new financings, Liechtenstein-based Pantec Biosolutions is gearing up for two Phase II clinical trials with hormone-based IVF therapies, to be delivered using transdermal patches in conjunction with the company's PLEASE (Painless Laser EpidermAl System) technology.
The series B financing was led by StemCell Holding, an Austrian venture capital company focused on the biomedical and high-technology...